MarketInOut Stock Screener Log In | Sign Up

Apnimed Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 11/17/2026 13:09
Apnimed Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization730.62 mln
Float31.25 mln
Earnings Date11/16/2026

EPS

7.22
Strong

P / E

2.43
Deeply undervalued

Relative Strength

97 / 100
Top performer

Debt / Equity

0.14
Very low leverage

Pre-Tax Margin

82%
Exceptional margin

ROE

79.72
Exceptional

Business Description

Apnimed is a pharmaceutical company focused on creating pill-based treatments for breathing disorders that occur during sleep. Its lead product, AD109, works by correcting the muscle and nerve dysfunction that causes obstructive sleep apnea, offering patients an alternative to traditional mechanical devices. Founded in 2017 and based in Cambridge, Massachusetts, the company aims to serve patients worldwide.

Key Fundamentals

EPS7.22
P/E2.43
ROE79.72
RPS9.63
ROIC64.39
ROA36.57
EBITDA, mln81.60
EV / EBITDA4.74
EV / EBIT4.74
Revenue, mln99.37
EV / Revenue3.89

Quote Details

Last 17.49
Change 1.21 (7.43%)
Open 16.03
Volume 215,146
Turnover 3,762,904
Average Volume 385,844

Financial Ratios

Pre-Tax Profit Margin82
Leverage Ratio1.30
Current Ratio9.77
Price / Book2.45
Price / Tangible Book2.45
Debt / Equity0.14
Price / Sales6.77

Financial Strength

Altman Z-Score5.85
Price to Graham Number0.96
Short Ratio3.72

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 10.28% 97 / 100   
1 Month 5.36% 86 / 100   
2 Months -34.37% 21 / 100   



Disclaimer - Privacy Policy - Terms of Service - Cookies - FAQ - Affiliates - Blog